Literature DB >> 34958370

p62/SQSTM1 promotes mitophagy and activates the NRF2-mediated antioxidant and anti-inflammatory response restraining EBV-driven B lymphocyte proliferation.

Maria Saveria Gilardini Montani1, Greta Tarquini1, Roberta Santarelli1, Roberta Gonnella1, Maria Anele Romeo1, Rossella Benedetti1, Andrea Arena1, Alberto Faggioni1, Mara Cirone1.   

Abstract

Reactive oxygen species (ROS) and DNA repair, respectively, promote and limit oncogenic transformation of B cells driven by Epstein-Barr virus (EBV). We have previously shown that EBV infection reduced autophagy in primary B lymphocytes and enhanced ROS and interleukin 6 (IL-6) release, promoting B-cell proliferation and immortalization. In this study, we explored the role of p62/SQSTM1, accumulated as a consequence of autophagy reduction in EBV-infected B lymphocytes, and found that it exerted a growth-suppressive effect in these cells. At the molecular level, we found that p62 counteracted IL-6 production and ROS increase by interacting with NRF2 and promoting mitophagy. Moreover, p62/NRF2 axis sustained the expression level of H2AX and ataxia-telangiectasia mutated (ATM), whose activation has been shown to have growth-suppressive effects during the first steps of EBV infection, before latency is established. In conclusion, this study shows for the first time that the accumulation of p62 and the activation of p62/axis counteracted EBV-driven proliferation of primary B lymphocytes.
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34958370     DOI: 10.1093/carcin/bgab116

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  2 in total

Review 1.  Interconnected Adaptive Responses: A Way Out for Cancer Cells to Avoid Cellular Demise.

Authors:  Gabriella D'Orazi; Mara Cirone
Journal:  Cancers (Basel)       Date:  2022-06-03       Impact factor: 6.575

2.  Concomitant Inhibition of IRE1α/XBP1 Axis of UPR and PARP: A Promising Therapeutic Approach against c-Myc and Gammaherpesvirus-Driven B-Cell Lymphomas.

Authors:  Rossella Benedetti; Andrea Arena; Maria Anele Romeo; Maria Saveria Gilardini Montani; Roberta Gonnella; Roberta Santarelli; Pankaj Trivedi; Mara Cirone
Journal:  Int J Mol Sci       Date:  2022-08-14       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.